An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts. (2020)
Attributed to:
MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22050
Publication URI: http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e22050
Type: Journal Article/Review
Parent Publication: Journal of Clinical Oncology
Issue: 15_suppl